• Article

An economic evaluation of ramipril in the treatment of patients at high risk for cardiovascular events due to diabetes mellitus

Cardiovascular disease (CVD) is a major cause of death and morbidity in the United Kingdom (UK) and carries with it a significant financial cost through health care resource use. More than one in three people die from CVD events, and the cost to the UK National Health Service (NHS) was £1.6 billion in 19961. The recently published MICRO-HOPE study evaluated the treatment of 3,577 patients at high risk for cardiovascular events from diabetes mellitus and demonstrated significant survival and morbidity benefits associated with ramipril.

Citation

Beard, S., Gaffney, L., & Backhouse, M. (2001). An economic evaluation of ramipril in the treatment of patients at high risk for cardiovascular events due to diabetes mellitus. Journal of Medical Economics, 4, 199-205.